PL365742A1 - Szczepienie przeciw wirusowi niedoboru odpornościkotów - Google Patents

Szczepienie przeciw wirusowi niedoboru odpornościkotów

Info

Publication number
PL365742A1
PL365742A1 PL02365742A PL36574202A PL365742A1 PL 365742 A1 PL365742 A1 PL 365742A1 PL 02365742 A PL02365742 A PL 02365742A PL 36574202 A PL36574202 A PL 36574202A PL 365742 A1 PL365742 A1 PL 365742A1
Authority
PL
Poland
Prior art keywords
gag
fiv
vaccine
pro
env
Prior art date
Application number
PL02365742A
Other languages
English (en)
Other versions
PL210450B1 (pl
Inventor
Laurent Bernard Fischer
Original Assignee
Merial
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial filed Critical Merial
Publication of PL365742A1 publication Critical patent/PL365742A1/pl
Publication of PL210450B1 publication Critical patent/PL210450B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL365742A 2001-06-01 2002-05-29 Zestaw do szczepienia kotowatych przeciwko wirusowi nabytego niedoboru immunologicznego kotów (FIV) oraz zastosowanie plazmidów i wektorów wirusowych zawierających i eksprymujących in vivo polinukleotydy do wytwarzania szczepionki PL210450B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0107275A FR2825280B1 (fr) 2001-06-01 2001-06-01 Vaccination contre le virus de l'immunodeficience feline
PCT/FR2002/001809 WO2002096349A2 (fr) 2001-06-01 2002-05-29 Vaccination contre le virus de l'immunodeficience feline

Publications (2)

Publication Number Publication Date
PL365742A1 true PL365742A1 (pl) 2005-01-10
PL210450B1 PL210450B1 (pl) 2012-01-31

Family

ID=8863923

Family Applications (1)

Application Number Title Priority Date Filing Date
PL365742A PL210450B1 (pl) 2001-06-01 2002-05-29 Zestaw do szczepienia kotowatych przeciwko wirusowi nabytego niedoboru immunologicznego kotów (FIV) oraz zastosowanie plazmidów i wektorów wirusowych zawierających i eksprymujących in vivo polinukleotydy do wytwarzania szczepionki

Country Status (14)

Country Link
EP (1) EP1418941B9 (pl)
JP (1) JP2004535406A (pl)
AT (1) ATE473013T1 (pl)
AU (1) AU2002314274B2 (pl)
BR (1) BRPI0210229B1 (pl)
CA (1) CA2448620C (pl)
CZ (1) CZ305257B6 (pl)
DE (1) DE60236943D1 (pl)
DK (1) DK1418941T3 (pl)
ES (1) ES2348226T3 (pl)
FR (1) FR2825280B1 (pl)
PL (1) PL210450B1 (pl)
PT (1) PT1418941E (pl)
WO (1) WO2002096349A2 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050214316A1 (en) 2003-11-13 2005-09-29 Brown Thomas P Methods of characterizing infectious bursal disease virus
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
US9925248B2 (en) 2013-08-29 2018-03-27 Temple University Of The Commonwealth System Of Higher Education Methods and compositions for RNA-guided treatment of HIV infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0758396B1 (en) * 1994-04-29 2006-07-26 Pharmacia & Upjohn Company LLC Feline immunodeficiency virus vaccine
US7255862B1 (en) * 1996-11-14 2007-08-14 Connaught Technology Corporation ALVAC/FIV constructs
AU782154C (en) * 1999-06-10 2006-02-09 Boehringer Ingelheim Animal Health USA Inc. DNA vaccines for pets and sport animals
EP1074625A3 (en) * 1999-06-14 2002-01-02 Pfizer Products Inc. DNA vaccine against feline immunodeficiency virus

Also Published As

Publication number Publication date
CA2448620C (en) 2013-05-28
BRPI0210229B1 (pt) 2016-11-22
DE60236943D1 (de) 2010-08-19
WO2002096349A3 (fr) 2004-03-11
ES2348226T3 (es) 2010-12-01
FR2825280B1 (fr) 2005-04-15
WO2002096349A2 (fr) 2002-12-05
CA2448620A1 (en) 2002-12-05
EP1418941B9 (fr) 2010-10-20
EP1418941B1 (fr) 2010-07-07
JP2004535406A (ja) 2004-11-25
PL210450B1 (pl) 2012-01-31
CZ305257B6 (cs) 2015-07-08
EP1418941A2 (fr) 2004-05-19
CZ20033229A3 (cs) 2004-03-17
FR2825280A1 (fr) 2002-12-06
PT1418941E (pt) 2010-10-12
AU2002314274B2 (en) 2008-03-20
DK1418941T3 (da) 2010-11-01
BR0210229A (pt) 2004-07-20
ATE473013T1 (de) 2010-07-15

Similar Documents

Publication Publication Date Title
ATE526411T1 (de) Avirulente, immunogene flavivirus-chimäre
NO992369D0 (no) Poxvirusbaserte ekspresjonsvektorer inneholdende heterologe innslag avledet fra lentivirus
ATE334216T1 (de) Impstoff gegen felines immunodefizienz-virus
AR003425A1 (es) Poxvirus recombinante de mapache, vacuna para uso en gatos y uso de poxvirus para preparar una vacuna util para evitar o para disminuir la enfermedad causada por el virus de inmunodeficiencia felina (fiv)
AP2000001828A0 (en) HIV-1 TAT, or derivatives thereof for prophylactic and therapeutic vaccination.
WO2004050856A3 (en) Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
HUP9900389A2 (hu) Rekombináns vaccinia vektorok keverékét tartalmazó HIV elleni polienv vakcinák
ZA200701176B (en) Vaccines against aids comprising CMV/R-nucleic acid constructs
WO1997048370A3 (en) Vaccines comprising synthetic genes
Kadkhodayan et al. Combination of cell penetrating peptides and heterologous DNA prime/protein boost strategy enhances immune responses against HIV-1 Nef antigen in BALB/c mouse model
BR0206823A (pt) Gene quimérico, proteìna quimérica, vìrus recombinante, composição de vacina, uso de uma composição de vacina, combinação terapêutica ou preventiva, e, plasmìdeo
TW200502245A (en) Vaccine
BR0206112A (pt) Vacinas de ácido nucléico usando ácidos nucléicos de codificação de antìgeno de tumor com ácido nucleìco de codificação de auxiliar de citocina
PL365742A1 (pl) Szczepienie przeciw wirusowi niedoboru odpornościkotów
DE50010240D1 (de) Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze
FR2829498B1 (fr) Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
WO2003089571A3 (en) Ehrlichia canis genes and vaccines
WO2005027844A3 (en) Dna vaccine compositions and methods of use
AU2003281917A8 (en) Vaccine against infections caused by oncoviruses such as the feline leucosis virus of cats
AU2018200081B2 (en) Avirulent, immunogenic flavivirus chimeras
WO1998042847A3 (de) Papillomvirus-hauptcapsid-proteins und deren verwendung in diagnose, therapie und vakzinierung
WO2002000250A3 (en) Hiv-1 vaccines and screening methods therefor
Sato et al. Efficient expression of the envelope protein of feline immunodeficiency virus in a recombinant feline herpesvirus type 1 (FHV-1) using the gC promoter of FHV-1
ATE419363T1 (de) Pharmazeitische impfstoffe gegen hiv
Wardley et al. Feline immunodeficiency virus vaccine